**Analysis:**

The earnings call for Amgen provides a detailed overview of the company's performance and future outlook. The company reported a challenging first quarter due to macroeconomic factors, including patient behavior changes and inventory adjustments. Key points include:

1. **Revenue Decline:** Revenue decreased by 8% compared to the same period last year, primarily due to Enbrel sales and inventory swings.
2. **Enbrel Performance:** Enbrel sales were down 20% year-over-year, with a significant portion of the decline attributed to inventory and demand factors, including the economy.
3. **International Performance:** International sales grew 9% (excluding divested products and foreign exchange effects), indicating strong performance in key markets.
4. **Guidance:** The company revised its full-year revenue guidance down to $14.4-$14.8 billion, reflecting the economic challenges and inventory adjustments.
5. **Cost Management:** Amgen emphasized its cost-cutting measures and the need to balance investment in R&D with operational efficiency.
6. **Pipeline Progress:** The company provided updates on its pipeline, including denosumab, Vectibix, and other products, indicating continued progress in clinical trials and regulatory interactions.

**Conclusion:**

The earnings call highlights the challenges Amgen is facing due to the economic downturn and market conditions. While the company has taken steps to manage costs and adjust its guidance, the outlook remains uncertain. The stock is likely to face short-term pressure due to the revised guidance and economic headwinds. However, the company's strong balance sheet and ongoing pipeline progress may provide some support in the long term.

**Rating:**

-1